A metabolic constraint in the kynurenine pathway drives mucosal inflammation in IBD

Lina Welz; Danielle MM Harris; Na-Mi Kim; Abrar I Alsaadi; Qicong Wu; Mhmd Oumari; Jan Taubenheim; Valery Volk; Graziella Credido; Eric Koncina; Pranab K Mukherjee; Florian Tran; Laura Katharina Sievers; Polychronis Pavlidis; Nick Powell; Florian Rieder; Elisabeth Letellier; Silvio Waschina; Christoph Kaleta; Friedrich Feuerhake; Bram Verstockt; Melanie R McReynolds; Philip Rosenstiel; Stefan Schreiber; Konrad Aden

doi:10.1101/2024.08.08.24311598

Summary

Inflammatory bowel disease (IBD) is associated with perturbed metabolism of the essential amino acid tryptophan (Trp). Whether increased degradation of Trp directly fuels mucosal inflammation or acts as a compensatory attempt to restore cellular energy levels via de-novo nicotinamide adenine dinucleotide (NAD⁺) synthesis is not understood. Employing a systems medicine approach on longitudinal IBD therapy intervention cohorts and targeted screening in preclinical IBD models, we discover that steady increases in Trp levels upon therapy success coincide with a rewiring of metabolic processes within the kynurenine pathway (KP). In detail, we identify that Trp catabolism in IBD is metabolically constrained at the level of quinolinate phosphorybosyltransferase (QPRT), leading to accumulation of quinolinic acid (Quin) and a decrease of NAD⁺. We further demonstrate that Trp degradation along the KP occurs locally in the inflamed intestinal mucosa and critically depends on janus kinase / signal transducers and activators of transcription (JAK/STAT) signalling. Subsequently, knockdown of QPRT in-vitro induces NAD⁺ depletion and a pro-inflammatory state, which can largely be rescued by bypassing QPRT via other NAD⁺ precursors. We hence propose a model of impaired de-novo NAD⁺ synthesis from Trp in IBD. These findings point towards the replenishment of NAD⁺ precursors as a novel therapeutic pathway in IBD.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the BMBF iTREAT project (P.R., C.K.), DFG Cluster of excellence (ExC2167) Precision medicine in chronic inflammation RTF III, RTF-VIII and TI-1, the DFG CRC 1182 C2 (P.R.), the EU project miGut-Health (P.R.), the EKFS research grant #2019_A09 and EKFS Clinician Scientist Professorship (K.A., 2020_EKCS.11), the BMBF (eMED Juniorverbund Try-IBD 01ZX1915A, 01ZX2215, K.A., D.H.), the DFG RU5042 (P.R., K.A., C.K.), the Joachim Herz Stiftung (K.A.), NIH Grant T32GM108563 (A.I.A.), the Howard Hughes Medical Institute Hanna H. Gray Fellows Program Faculty Phase (Grant# GT15655, M.R.M), the Burroughs Welcome Fund PDEP Transition to Faculty (Grant# 1022604, M.R.M), the ECCO Multiyear Research Grant 2021 (K.A., B.V). and the Clinical Research Fund (KOOR) at the University Hospitals Leuven and the Research Council at the KU Leuven (B.V.). This project has furthermore received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853995 (ImmUniverse). The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Clinical studies conducted at the University Hospital Schleswig-Holstein, Campus Kiel, were approved by the ethics committee of the Christian Albrecht University of Kiel (D 490/20, D 489/20, A 124/14 and AZ 156/03-2/13) in accordance with the Declaration of Helsinki and all enrolled subjects provided written informed consent

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

↵+ Shared senior authorship
Grant support This work was supported by the BMBF iTREAT project (P.R., C.K.), DFG Cluster of excellence (ExC2167) “Precision medicine in chronic inflammation” RTF III, RTF-VIII and TI-1, the DFG CRC 1182 C2 (P.R.), the EU project miGut-Health (P.R.), the EKFS research grant #2019_A09 and EKFS Clinician Scientist Professorship (K.A., 2020_EKCS.11), the BMBF (eMED Juniorverbund “Try-IBD” 01ZX1915A, 01ZX2215, K.A., D.H.), the DFG RU5042 (P.R., K.A., C.K.), the Joachim Herz Stiftung (K.A.), NIH Grant T32GM108563 (A.I.A.), the Howard Hughes Medical Institute Hanna H. Gray Fellows Program Faculty Phase (Grant# GT15655, M.R.M), the Burroughs Welcome Fund PDEP Transition to Faculty (Grant# 1022604, M.R.M), the ECCO Multiyear Research Grant 2021 (K.A., B.V). and the Clinical Research Fund (KOOR) at the University Hospitals Leuven and the Research Council at the KU Leuven (B.V.). This project has furthermore received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853995 (ImmUniverse). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.